Edwards Lifesciences (NYSE:EW) updated its second quarter earnings guidance on Tuesday. The company provided earnings per share guidance of $1.27-1.37 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.33. The company issued revenue guidance of $1.02-1.08 billion, compared to the consensus revenue estimate of $1.04 billion.Edwards Lifesciences also updated its FY 2019 guidance to $5.10-5.35 EPS.

NYSE:EW traded up $2.71 during trading hours on Tuesday, hitting $180.98. 1,502,762 shares of the stock traded hands, compared to its average volume of 1,325,963. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.61 and a quick ratio of 1.92. Edwards Lifesciences has a 1 year low of $123.00 and a 1 year high of $197.86. The company has a market capitalization of $36.88 billion, a P/E ratio of 38.51, a P/E/G ratio of 2.31 and a beta of 0.91.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.10. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. The business had revenue of $993.00 million for the quarter, compared to the consensus estimate of $989.87 million. During the same quarter in the previous year, the firm earned $1.22 earnings per share. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. On average, sell-side analysts anticipate that Edwards Lifesciences will post 5.22 earnings per share for the current fiscal year.

Several research firms have recently commented on EW. Credit Suisse Group boosted their target price on shares of Edwards Lifesciences from $189.00 to $221.00 and gave the stock an outperform rating in a report on Monday, April 15th. Canaccord Genuity reissued a buy rating and issued a $215.00 target price (up previously from $190.00) on shares of Edwards Lifesciences in a report on Monday, March 18th. Stifel Nicolaus reissued a buy rating and issued a $190.00 target price on shares of Edwards Lifesciences in a report on Sunday, February 3rd. Barclays boosted their target price on shares of Edwards Lifesciences from $150.00 to $160.00 and gave the stock an underweight rating in a report on Monday, March 25th. Finally, BMO Capital Markets boosted their target price on shares of Edwards Lifesciences to $204.00 and gave the stock an outperform rating in a report on Friday, March 22nd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $182.29.

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 32,800 shares of the business’s stock in a transaction on Tuesday, February 12th. The shares were sold at an average price of $176.90, for a total transaction of $5,802,320.00. Following the transaction, the chief executive officer now owns 75,926 shares in the company, valued at $13,431,309.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Catherine M. Szyman sold 1,474 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $192.00, for a total transaction of $283,008.00. Following the transaction, the vice president now owns 21,132 shares in the company, valued at approximately $4,057,344. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 114,328 shares of company stock worth $20,121,304. 1.63% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/edwards-lifesciences-ew-updates-q2-earnings-guidance/2983009.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: Put Option Volume

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.